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Abstract
Purpose Cereboost®, an American ginseng extract, has shown improved short-term memory and attention/alertness in 
healthy young and middle-aged individuals, potentially via modulation of the gut microbiome and upregulation of neuro-
transmitters such as acetylcholine. Here, we explored the effects of Cereboost® on cognition and mood in the first 6 h post 
intervention (acute), after 2 weeks daily supplementation (chronic), and whether 2 weeks daily supplementation altered the 
response to a single acute dose (acute-on-chronic). A concurrent in vitro study evaluated effects of repeated Cereboost® 
administration on human gut microbiota.
Methods Cognitive effects of Cereboost® were assessed using a double-blind, randomized, placebo-controlled clinical 
trial, with 61 healthy young adults. Modulation of the gut microbiome was concurrently modelled using the Simulator of 
the Human Microbial Ecosystem (SHIME®), using a young adult donor.
Results Consistent with previous findings, Cereboost® improved working memory and attention during the immediate 
postprandial period; effects that were amplified following two weeks’ treatment (acute-on-chronic) compared to acute test-
ing alone. Chronic supplementation improved cognition on an acetylcholine-sensitive attention task and improved mental 
fatigue and self-assurance aspects of mood. The parallel in vitro study revealed significantly increased acetate, propionate, 
and butyrate levels in simulated proximal and distal colon regions, linked with observed increases in Akkermansia mucin-
iphila and Lactobacillus.
Conclusion This study confirmed the promising effects of Cereboost® on cognitive function and mood, while suggesting a 
possible link to alterations of the gut microbiome and modulation of acetylcholine. Further studies will be required to unravel 
the underlying mechanisms that are involved.
Registration The study was pre-registered at ClinicalTrials.gov on 6th July 2018 (Identifier: NCT03579095).
Keywords American ginseng · Cognition · Mood · Gut microbiome · SCFA
Introduction
Ginseng is a globally popular herbal root extract obtained 
from plants of the Panax family [1]. It is widely regarded as 
a panacea in traditional medicine and has been used for cen-
turies to treat mental and physical ailments, and promote lon-
gevity [2]. Ginseng contains a number of bioactives including 
flavonoids and other phenolic compounds, essential oils, and 
vitamins [3]. However, the main bioactive ingredients in gin-
seng are purported to be ginsenosides including Rb1, Re, Rd, 
and F11. There are multiple species of ginseng which can be 
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distinguished by their profiles of these ginsenoside subtypes 
[4]. American ginseng (Panax quinquefolius) provides a par-
ticularly rich source of these ginsenoside types when compared 
to other ginseng varieties [5].
Emerging research suggests that supplementation with P. 
quinquefolius may elicit cognitive enhancement effects. Studies 
have typically investigated the benefits of Cereboost®, a standard-
ised extract of American ginseng, although only acute benefits have 
been investigated to date. For example, following acute supplemen-
tation with 100 mg, 200 mg and 400 mg Cereboost®, improve-
ments on an immediate word recall task, a visuospatial working 
memory task, a choice reaction time task, a composite working 
memory factor, and a measure of subjective mood (i.e. calmness) 
were observed in healthy young adults (aged 18–40 years) during 
the six hours after consumption [6]. Adding to these findings, a 
study of middle-aged adults (aged 40–60 years) observed similar 
acute benefits of 200 mg Cereboost® on a composite working 
memory factor after three hours [7], although no changes in mood 
were observed in this older age group.
There is currently limited in vitro and in vivo research 
investigating possible mechanisms of action for observed 
improvements to mood and cognition following treatment 
with P. quinquefolius. Two mechanisms have been proposed 
to date; blood glucose regulatory effects [8–11], and effects 
on acetylcholine-related pathways of neurotransmission 
[12, 13]. The latter mechanism is of particular interest as 
Rb1, an abundant ginsenoside in P.quinquefolius, has been 
associated with upregulation of cholinergic pathways [14, 
15]. Such cholinergic systems are known to be important in 
modulating cognitive functions [16], including learning and 
memory [4], and attention [17].
The timing and strength of cognitive benefits following 
treatment with ginseng are likely to be strongly dependent on 
the metabolism, and thus subsequent bioavailability, of the 
ginsenosides present. Ginsenosides, such as Rb1, are known to 
be absorbed from the upper gastrointestinal tract [18]. A study 
investigating the oral administration of American ginseng in 
healthy adults (age not specified) found Rb1 to be present in 
plasma samples throughout a 2–12-h period after administra-
tion [19]. Cognitive enhancement associated with American 
ginseng supplementation may also arise from compound K, 
an active metabolite of ginsenoside Rb1 [20], which is detect-
able in human plasma following oral consumption [21]. Rb1 
is converted into compound K by intestinal bacteria through 
a process of deglycosylation and fatty acid esterification [22]. 
However, this process is dependent on an individual’s gut 
microbiota profile, which in turn may be determined by diet. 
For example, greater ratios of compound K to Rb1 have been 
observed in plasma, urine and faeces following consumption 
of American ginseng when regularly consuming a western diet 
rather than an Asian diet [23]. The regular consumption of 
ginseng is also likely to beneficially alter the gut microbiome 
[24, 25] and emerging evidence suggests that the microbiome 
is involved in brain development and cognitive function via 
the gut-brain axis. Mechanisms include production of neuro-
transmitters and short-chain fatty acid (SCFA) metabolites, 
that are implicated in brain function [26]. Positive changes to 
the microbiome may therefore also benefit cognitive function. 
However, this is yet to be investigated with respect to ginseng 
supplementation in a young-adult population.
The cognitive and mood benefits of P. quinquefolius remain 
under investigation, with exploration of repeated daily (chronic) 
supplementation seemingly a significant omission in the current 
datasets. Therefore, we aimed to investigate the acute, chronic, 
and acute-on-chronic benefits of 200 mg Cereboost® in healthy 
young adults (aged 18–40 years). This population has previ-
ously demonstrated sensitivity-to-acute supplementation with 
Cereboost®, during a six-hour period after consumption [6]. 
In the current study, testing of mood and cognitive function 
was therefore performed in the immediate postprandial period 
at 2 h, 4 h and 6 h following Cereboost® or placebo. These 
acute and acute-on-chronic test visits took place before and 
after daily supplementation for a pilot investigatory period of 
14 days, respectively (Experiment 1). It was hypothesized that 
daily supplementation with Cereboost® would improve cogni-
tive function and mood. It was also speculated that previously 
observed acute benefits to mood and cognition [6, 7] might be 
enhanced following the 14-day period of daily supplementa-
tion, as any beneficial changes in gut microbiota might lead to 
improved metabolism and subsequent bioavailability of the bio-
active compounds such as ginsenosides present in Cereboost®. 
Although 14 days appears a relatively short intervention dura-
tion, changes to gut microbiota are known to occur relatively 
quickly, in only hours, or days following dietary changes [27]. 
To investigate whether Cereboost® might indeed impact gut 
microbiota during such a short timeframe, a concurrent in vitro 
study was performed (Experiment 2). The SHIME® technol-
ogy platform was used to model changes in the human micro-
biome, using a faecal sample obtained from a healthy young 
adult donor, and following the same daily dosing with 200 mg 
Cereboost® for a similar intervention duration with weekly 
microbial sampling up to 21 days. It was hypothesized that 
the composition of the gut microbiota would be beneficially 
affected, resulting in a greater abundance of SCFA microbial 




Sample size was determined by power analysis assuming a 
moderate effect size (d = 0.65), obtained from a meta-analysis 
of P.ginseng effects on cognitive function [28]. A minimum 
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of 60 participants were required to achieve a statistical power 
of 80% when comparing treatment and placebo group scores. 
An initial screening target of 80 allowed for 15% ineligibility 
or dropout. Following screening, 63 healthy participants, aged 
18–40 years, 15 males, were recruited from students at Uni-
versity of Reading. Full demographic information is reported 
in Table 1. Exclusion criteria included food allergies, diabetes, 
psychiatric disorders, gastrointestinal disorders, and those tak-
ing any medication other than oral contraceptives. Participants 
were required to have a healthy BMI and to be non-smokers 
and non-vegetarians (due to the presence of gelatine in the 
intervention capsules). Participants were not permitted to take 
any additional supplements for the duration of the study, com-
mencing at screening. Health criteria were determined via 
self-report questionnaire except for BMI which was meas-
ured by a researcher. Participants were requested to notify the 
researcher of any changes to their health or medication status 
over the course of the study.
Design
The study design is shown in Fig. 1. Participants were ran-
domized to receive either 200 mg Cereboost® treatment 
or a placebo, using a block design with a block size of 4 
and an allocation ratio of 1:1. Participants and researchers 
were blind to the allocation which was implemented using 
sequentially numbered containers prepared independently 
by Naturex SA. Participants attended a screening visit where 
they were familiarised with the mood and cognitive tasks by 
completing the full task battery twice to reduce the likeli-
hood of practice effects impacting the test data [29]. During 
a break between these two familiarisation sessions, partici-
pants completed demographic and habitual diet question-
naires. One week later, during the first test visit, mood and 
cognitive testing was performed at baseline (session 1), then 
2 h, 4 h and 6 h following acute supplementation (sessions 2, 
3, and 4, respectively). Participants then took supplements 
daily (1 capsule each morning with their breakfast) for a 
2-week chronic intervention period, followed by a second 
test visit where mood and cognitive testing was repeated at 
baseline (session 5), then 2 h, 4 h, and 6 h following acute-
on-chronic supplementation (sessions 6, 7, and 8, respec-
tively). Participants attended each test visit in an overnight 
fasted state, having followed a low-polyphenol diet for 48 h.
Treatments
The opaque Cereboost® capsules contained 200  mg 
of P. quinquefolius extract standardised for ginsenosides 
(10–12%) in accordance with patent US 8,968,800 B2. The 
placebo capsules were identical in appearance but contained 
only maltodextrin. Both sets of capsules were prepared by 
Naturex SA.
Cognitive task battery
The computerized cognitive battery was presented using 
E-Prime 2.0 software (Psychology Software Tools, Pitts-
burgh, PA), and comprised tasks previously demonstrated to 
be sensitive to nutritional interventions. Cognitive domains 
targeted included attention, working memory, episodic 
memory, and mood. The battery took 30–40 min to com-
plete at each test session. Ten equivalent versions of the 
battery, presented in counterbalanced order, were created to 
minimise practice effects between test sessions. The tasks 
are described in the order in which they appeared in the 
task battery.
PANAS‑X (initially measured at the screening visit, then 
again at baseline on the final test visit)
The PANAS-X [30] is a self-report questionnaire consisting 
of 60 mood-related adjectives and is a recognised measure 
Table 1  Participant 
demographic information
Data presented as mean ± SD or frequency ratio, p values calculated using independent samples  t-test or 
Chi-square statistic, ns indicates non-significance (p > 0.05)
Cereboost® group Placebo group p value
(n = 30) (n = 31)
Age (years) 20.6 ± 2.4 20.5 ± 2.7 ns
Gender (F:M) 23:7 23:8 ns
Body weight (kg) 62.7 ± 9.4 63.7 ± 12.5 ns
Height (cm) 170.3 ± 8.4 166.5 ± 9.4 ns
BMI (kg/m2) 21.6 ± 2.3 22.9 ± 3.6 ns
Habitual fruit and veg consumption (por-
tions/day)
5.9 ± 2.2 5.3 ± 2.8 ns
Habitual calorie intake (kCal/day) 1524 ± 424 1520 ± 629 ns
Habitual NSP fibre intake (g/day) 13.6 ± 2.5 14.5 ± 7.4 ns
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of trait mood. Participants rated their general mood over the 
last 2 weeks on a 5-point Likert Scale from “not at all” to 
“very much” for each item. Mood factor scores for Fear, Sad-
ness, Guilt, Hostility, Shyness, Fatigue, Surprise, Joviality, 
Self-Assurance, Attentiveness, and Serenity were obtained, 
in addition to Positive Affect and Negative Affect scores like 
those derived for the PANAS-Now questionnaire.
Positive and Negative Affect Schedule Now (PANAS—Now)
The PANAS-Now questionnaire [31] is regarded as a reli-
able measure for examining current (or state) mood in non-
clinical populations. During the task, participants were 
asked to rate 20 mood-related adjectives, indicating the 
extent to which they were currently experiencing that emo-
tion on a 5-point Likert scale, ranging from “not at all” to 
“very much”. Half of the presented words related to posi-
tive emotions, the other half to negative emotions. Separate 
scores were obtained for positive affect and negative affect 
by summing ratings for all similarly valanced words. The 
PANAS-Now questionnaire was completed at the beginning 
(PANAS-Now 1) and end of the task battery (PANAS-Now 
2), at each cognitive testing session.
Subjective mental fatigue
An additional item was added to the questionnaire to meas-
ure mental fatigue using a 9-point Likert scale [6]. Anchor 
points on the scale were ‘1. Not at all mentally fatigued’ and 
‘9. Extremely mentally fatigued’. As with the PANAS-Now 
questionnaire, mental fatigue ratings were recorded at the 
beginning (mental fatigue 1) and end of the task battery 
(mental fatigue 2), at each cognitive testing session.
Immediate word recall
In this previously published episodic memory task [6], partici-
pants were visually presented with a sequential list of fifteen 
words. The participants were then given 1 min to type as many 
of the words as they could remember. A different word list, 
matched for linguistic familiarity, concreteness and frequency, 
was presented at each sitting of the task. The dependent vari-
able was the number of correctly recalled words.
Corsi block tapping task
This visuo-spatial working memory task was a computerised 
version of the original Corsi Blocks task [32]. In the task, nine 
squares were presented on screen in a fixed position. Across 
multiple trials, a varying number of these squares flashed 
sequentially in quasi-random order. Participants viewed spa-
tial sequences ranging from two to nine blocks. The partici-
pants were required to immediately repeat each sequence by 
clicking on the correct squares in the same order. The depend-
ent variable was the number of correct sequences recalled.
Attention network task (ANT)
In this measure of executive function and attention [33], par-
ticipants responded to the direction of a centrally presented 
Fig. 1  Study design: Timeline A 
represents the complete chronic 
study design; Timeline B repre-
sents the design of each acute or 
acute-on-chronic test visit (test 
visits 1 and 2, respectively). The 
cognitive test battery performed 
at each test visit consisted of 
PANAS-Now; immediate, and 
delayed word recall; Corsi 
blocks; attention network task; 
and switching task. In addition, 
PANAS-X was performed at 
the screening visit and again at 
baseline on test visit 2
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target arrowhead by pressing the corresponding left and 
right arrow keys. Across multiple trials, the target stimulus 
was either flanked by arrows pointing in the same direc-
tion (congruent), or the opposite direction (incongruent). 
The number of flanking arrows also varied between trials 
(load). The task was completed in two blocks. During the 
second block, participants were distracted by noise through 
headphones. The dependent variables were reaction time and 
accuracy by congruency, load, and noise.
Rapid visual information processing task (RVIP)
In this sustained attention task [34], a series of digits were 
presented on screen in quick succession. The participant was 
required to monitor the digits for sequences of three con-
secutive even or three consecutive odd digits. Participants 
indicated the end of a target sequence by pressing the space 
bar as quickly as possible. The dependent variables were 
reaction time, correct responses, and commission errors. 
This task is reported to be an acetylcholine-sensitive task 
[6, 35] and has been shown to be sensitive to P.ginseng [36] 
and so was selected to be the primary outcome measure.
Switching task
This previously published task assessed executive function 
[37]. Participants viewed a circle with 8 equally spaced radii 
that formed 8 segments, 4 above and 4 below a bold line. 
A stimulus digit appeared sequentially in each segment in a 
clockwise direction. If the digit was located above the bold 
line, participants indicated whether the digit was odd or even 
using labelled arrow keys (left for odd, right for even). When 
the digit was below the bold line, participants again used the 
arrow keys to indicate whether the digit was higher or lower 
than 5 (left for higher, right for lower). Dependent variables 
were accuracy and reaction time.
Delayed word recall
As a measure of delayed episodic memory, participants were 
asked to type as many words as they could remember from 
the immediate recall word presentation. The task took place 
approximately 30 min after the initial presentation.
Procedure
Testing took place in the Nutritional Psychology Unit at the 
School of Psychology & Clinical Languages, University 
of Reading. Each participant was required to visit the unit 
on three separate occasions (Fig. 1). The first visit was a 
screening visit where informed consent was obtained from 
all participants before completing a demographics question-
naire and a measure of habitual diet (EPIC-Norfolk food 
frequency questionnaire [38]). Participants were then given 
the opportunity to familiarise themselves with the cognitive 
tasks to minimise the impact of practice effects [29]. Partici-
pants returned approximately 1 week later for their first test 
visit and then again two weeks later for the final test visit. 
For 48 h prior to each test visit, participants were required 
to follow a low polyphenol diet and keep a food diary of 
everything they consumed as a record of dietary compliance. 
Alcohol and caffeine were restricted for 24 h only.
Participants arrived at the test visits in an overnight fasted 
state and were provided with a standardised breakfast (2 
croissants and a glass of water) before performing base-
line cognitive testing. Participants then received a capsule 
(either placebo or treatment depending on randomisation). 
Cognitive testing was then repeated 2 h, 4 h, and 6 h post 
intervention. A light standardized lunch was provided at the 
end of the 2 h session, which consisted of a cheese sand-
wich, a packet of ready salted crisps, and a glass of water. 
At the end of the first test visit, participants were provided 
with 2 weeks’ worth of placebo or treatment capsules to take 
home. They were instructed to take one every morning with 
breakfast and not to take one on the morning of the final test 
visit. Unused capsules were returned to monitor compliance. 
At the end of the final test visit, participants were awarded 
course credit for their participation.
Safety
Participants were asked to report any negative health prob-
lems experienced throughout the course of the study. No 
issues were reported.
Statistics
Data were analysed using SPSS statistics, version 25.0 (IBM 
Corporation). An intention-to-treat (ITT) analysis method 
incorporated all available data for each participant under the 
group they were assigned. Separate analyses were performed 
to test the acute, chronic, and acute-on-chronic effects of 
Cereboost® on all cognitive and mood-dependent vari-
ables. Further analysis compared acute effects with acute-
on-chronic effects. Prior to each analysis, z scores were cal-
culated to identify and remove any outlier data points with z 
score > 3.29. The procedure was performed twice for tasks 
with a small number of extreme outliers (ANT and Switch-
ing task) [52]. A linear marginal model (LMM), using an 
unstructured covariance matrix to model repeated response 
measures for each participant, was used to analyse all data. 
Baseline performance was included as a covariate.
Acute: Baseline data recorded at the first test visit (ses-
sion 1) were entered as a covariate for the acute analysis. 
Treatment and placebo group scores were compared for data 
collected at sessions 2, 3, and 4, which corresponded to 2 h, 
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4 h, and 6 h post-prandial time points, respectively. Fixed 
factors included in the model were Baseline, Session, Treat-
ment, and Session x Treatment interaction.
Chronic: For the chronic analysis, baseline data recorded 
at the first test visit (session 1) were entered as a covariate. 
Treatment and placebo group scores were compared at ses-
sion 5. Fixed factors were Baseline and Treatment.
Acute-on-chronic: Baseline data recorded at the second 
test visit (session 5) were included as a covariate for the 
acute-on-chronic analysis. This analysis compared treatment 
and placebo group performance at sessions 6, 7, and 8 (again 
corresponding to 2 h, 4 h, and 6 h post-prandial timepoints). 
Fixed factors in the model were Baseline, Session, Treat-
ment, and Session × Treatment interaction.
Comparison between acute and acute-on-chronic: For 
the additional analysis comparing acute data with acute-
on-chronic data, a repeated baseline covariate was used 
incorporating baseline data from the first and second test 
visits (session 1 and session 5 data). Visit was included as 
an additional fixed factor in the model, alongside Baseline, 
Session, Treatment, and Session × Treatment interaction.
For the ANT task, congruency, load, noise and their 
respective treatment interactions were also included as 
fixed factors in all of the above analysis models. Post hoc, 
Bonferroni corrected, pairwise comparisons were used to 
investigate all significant treatment-related effects (p < 0.05). 
Cohen’s d effect sizes with 95% CI [LL, UL] were calculated 
for all significant pairwise comparisons between Cereboost® 
and placebo treatments.
Results
Recruitment and data collection took place from May to 
August 2018. The trial ended when the required sample 
size was achieved. Sixty-three participants were recruited in 
total, however 2 participants failed to attend any test visits. 
The data for 61 participants were included in an ITT analy-
sis. The CONSORT Diagram is shown in Fig. 2. Participant 
demographic information is shown in Table 1.
Only statistically significant findings from the primary 
and secondary outcome measures are presented here. Esti-
mated marginal means and standard errors for all tasks and 
timepoints (including those with non-significant findings) 
are available in Supplemental Table S1.
Acute analysis
Significant acute findings are shown in Fig. 3. For per-
formance accuracy during the ANT task, the acute analy-
sis revealed significant treatment [F(1,414.98) = 20.50, 
p < 0.001], and treatment × session [F(2,409.60) = 4.70, 
p = 0.010] effects. Pairwise comparisons revealed accuracy 
to be greater following Cereboost® treatment at the 4 h and 
6 h test sessions (p = 0.001 and p < 0.001, respectively). 
Effect sizes were d = 0.96 [0.30, 1.39] at 4 h and d = 1.25 
[0.68, 1.81] at 6 h. A significant reduction in accuracy was 
observed for the placebo treatment between the 2 h and 4 h 
sessions (p = 0.044), and between the 2 h and 6 h sessions 
(p = 0.001), suggestive of an acute maintenance effect of 
Cereboost® treatment. A significant treatment x congru-
ency effect [F(1,414.96) = 20.63, p < 0.001] also revealed 
that Cereboost® treatment outperformed placebo treat-
ment on incongruent trials (p < 0.001; d = 1.63 [1.03,2.22]), 
indicating a benefit on more cognitively challenging trials. 
For ANT reaction time, the acute analysis revealed a sig-
nificant treatment × session interaction [F(2,433.97) = 3.57, 
p = 0.029]. Pairwise comparisons indicated faster reaction 
times for the Cereboost® treatment at the 2 h test session 
(p = 0.025; d = 0.60 [0.07,1.13]), compared with the placebo 
treatment. However, reaction times for the placebo treatment 
were observed to speed up between 2 and 6 h (p = 0.016), 
and between 4 and 6 h (p = 0.049). No acute benefits of Cer-
eboost® were observed for the primary RVIP task, Corsi 
blocks, mood measures, the switching task, or immediate 
and delayed recall.
Chronic analysis
Significant chronic findings are shown in Fig. 4. For the pri-
mary outcome measure, chronic Cereboost® supplementa-
tion for 14 days resulted in significantly fewer RVIP commis-
sion errors compared to placebo [F(1,55) = 4.22, p = 0.045]; 
d = 0.55 [0.03,1.07]. Similarly, a significant effect of treat-
ment on ANT accuracy was observed [F(1,433) = 6.29, 
p = 0.012] with Cereboost® outperforming placebo follow-
ing 14 days treatment, d = 0.66 [0.14,1.18]. Unlike accuracy, 
however, no significant chronic effects were seen for ANT 
reaction time. The mood analysis revealed significant treat-
ment effects for mental fatigue 1 [F(1,58) = 6.07, p = 0.017], 
which was mirrored in the PANAS-X fatigue measure 
[F(1,58) = 6.48, p = 0.014]. The PANAS-X self-assurance 
measure was also significant [F(1,58) = 5.84, p = 0.019]. 
In all cases, mood was better for the Cereboost® treatment 
compared with the placebo treatment. Effect sizes were 
d = 0.65 [0.13,1.18] for mental fatigue 1, d = 0.68 [0.15,1.20] 
for PANAS-X fatigue, and d = 0.64 [0.12,1.17] for PANAS-
X self-assurance. No chronic effects were observed for Corsi 
blocks, the switching task, or immediate and delayed recall.
Acute‑on‑chronic analysis
Significant acute-on-chronic findings are shown in Figs. 3 
and 5. For the ANT task, a significant effect of treatment was 
observed for accuracy performance [F(1,369.09) = 20.76, 
p < 0.001]. Pairwise comparisons indicated significantly 
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better performance for the Cereboost® treatment compared 
to placebo at all postprandial test sessions (2 h, p = 0.001; 
4 h, p = 0.003; 6 h, p < 0.001). Effect sizes were d = 0.85 
[0.30,1.39] at 2 h, d = 0.77 [0.23,1.31] at 4 h, and d = 1.05 
[0.49–1.61] at 6 h. A significant reduction in accuracy was 
observed for the placebo treatment between the 2 h and 6 h 
sessions (p = 0.046), and between the 4 h and 6 h sessions 
(p = 0.035). For ANT reaction time, a significant treatment 
effect was observed [F(1,401.45) = 14.43, p < 0.001], with 
overall faster performance for the Cereboost® treatment 
compared with the placebo treatment. Pairwise compari-
sons revealed consistently faster performance for the Cer-
eboost® treatment at all three test sessions (2 h, p = 0.032; 
4 h, p < 0.001; 6 h, p = 0.036). Effect sizes were d = 0.59 
[0.05,1.12] at 2 h, d = 1.30 [0.72,1.88] at 4 h, and d = 0.57 
[0.04,1.11] at 6  h. Cereboost® reaction times sped up 
between 2 and 4 h (p < 0.001) but slowed again between 4 
and 6 h (p = 0.001). The switching task revealed a significant 
effect of treatment for task reaction time [F(1,55.29) = 4.51, 
p = 0.038], with overall faster performance for the Cer-
eboost® treatment compared with the placebo treatment. 
Pairwise comparisons indicated a trend for faster reaction 
times at the 2 h session (p = 0.064; d = 0.52 [-0.02,1.05]). 
The Corsi Blocks analysis revealed a significant treatment x 
session interaction for sequence accuracy [F(2,56) = 4.072, 
p = 0.022]. Pairwise comparisons indicated significantly 
better performance at 4 h for the Cereboost® treatment 
(p = 0.029; d = 0.61 [0.08,1.15]). Performance decreased 
Fig. 2  CONSORT diagram
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between 2 and 4 h for the placebo treatment (p = 0.013), 
although it rose again between 4 and 6 h for the final test 
session of the study (p = 0.012), suggestive of more stable 
performance across the course of the day following Cere-
boost® treatment compared to placebo. No acute-on-chronic 
benefits of Cereboost® were observed for the primary RVIP 
task, mood measures, or immediate and delayed recall.
Comparison between acute and acute‑on‑chronic 
benefits
Significant comparisons between acute and acute-on-chronic 
effects are shown in Fig.  3. While acute benefits were 
observed for only a single task (ANT), acute-on-chronic ben-
efits were observed for 3 of the tasks (ANT, Corsi, Switching 
task) suggesting a possible enhancement of acute effects fol-
lowing a period of chronic supplementation. For the ANT 
task, accuracy scores as reported above were higher for 
Cereboost® treatment compared with placebo at two of the 
testing timepoints during acute testing at Visit 1, but these 
accuracy benefits were extended to all three time points dur-
ing acute-on-chronic testing at Visit 2. Indeed, a direct com-
parison between acute and acute-on-chronic results for ANT 
accuracy revealed a significant treatment x session x con-
gruency x visit interaction [F(11,800.28) = 2.86, p = 0.001], 
with a drop in performance between Visit 1 and Visit 2 for 
the placebo treatment at 6 h on congruent trials (p = 0.032); 
in contrast, a maintenance of performance was observed 
for the Cereboost® treatment. For ANT reaction times 
as reported above, responses were faster for Cereboost® 
Fig. 3  Maintenance of ANT accuracy and improved ANT reaction 
times observed in the immediate postprandial period following both 
acute and acute-on-chronic treatment with Cereboost® versus pla-
cebo. Comparison suggests that acute-on-chronic benefits observed 
at visit 2 are stronger than acute benefits observed at visit 1. Base-
line values are included as a covariate, *indicates a significant differ-
ence between time points or treatments (p < 0.05), error bars represent 
mean standard error
European Journal of Nutrition 
1 3
Fig. 4  Group differences in RVIP, ANT, and subjective mood per-
formance, observed at visit 2 following 14 days of chronic treatment 
with Cereboost® versus placebo. Baseline values are included as a 
covariate, *indicates a significant difference between time points or 
treatments (p < 0.05), error bars represent mean standard error
Fig. 5  Maintenance of Corsi sequence accuracy and improved 
switching task reaction times observed at visit 2 in the immediate 
postprandial period following acute-on-chronic treatment with Cer-
eboost® versus placebo. Baseline values are included as a covariate, 
*indicates a significant difference between time points or treatments 
(p < 0.05), error bars represent mean standard error
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treatment compared with placebo at only one of the testing 
timepoints during acute testing at Visit 1, but these reaction 
time benefits were extended to all three time points dur-
ing acute-on-chronic testing at Visit 2. Further analysis of 
the comparison between acute and acute-on-chronic results 
for ANT reaction times revealed a significant treatment x 
session x visit interaction [F(2,817.96) = 23.05, p = 0.048], 
where faster performance was observed for the Cereboost® 
treatment at Visit 2 compared with Visit 1 (p < 0.001), spe-




All chemicals were obtained from Sigma-Aldrich (Overijse, 
Belgium) unless stated otherwise. Naturex SA provided the 
Cereboost® treatment, which was tested at an in vitro dose 
of 200 mg per day, introduced as an aqueous solution.
Simulator of the Human Intestinal Microbial 
Ecosystem (SHIME®)
The reactor configuration of the current experiment was 
adapted from the SHIME® protocol (ProDigest and Ghent 
University, Belgium) [39]. The present SHIME® setup 
consisted of a succession of three reactors simulating the 
different regions of the gastrointestinal tract, i.e., upper gas-
trointestinal tract including subsequent stomach and small 
intestinal simulation, proximal colon (PC) and distal colon 
(DC), respectively. Inoculum preparation, feeding regime, 
retention times, pH, temperature settings and nutritional 
medium composition have been previously outlined [40]. A 
faecal sample was obtained from a healthy, male donor, aged 
34 years, and following an omnivorous Western diet. Upon 
introduction of the sample to the SHIME® system, a two-
week stabilization period was initiated to allow the faecal 
microbiome to differentiate in the colonic reactors depend-
ing on the local environmental conditions. To simulate both 
the luminal and mucus-associated microbial community, 
mucin beads were included in the PC and DC to mimic the 
mucus layer as previously described [41]. Following the 
stabilization period, the experimental design included a 
two-week control period to determine baseline parameters. 
During these phases, the simulator was fed daily with a 
standard nutrient matrix. The control period was followed 
by a three-week treatment period where supplementation 
with 200 mg Cereboost® took place once per day in addition 
to the standard nutrient feed.
Microbial metabolic activity
During the control and treatment period, samples for micro-
bial metabolic activity were collected three times per week 
from the PC and DC. Analysis of SCFA levels, including 
acetate, propionate, butyrate, and total SCFA (including the 
previously mentioned SCFA as well as valerate, caproate, 
isobutyrate, isovalerate and isocaproate), was conducted as 
previously reported [42].
Microbial community analysis
Starting from the control period, samples for microbial com-
munity analysis were collected once per week from each 
colon vessel. DNA was isolated using a previously described 
method [43], with some minor modifications. Luminal DNA 
was extracted from pelleted bacterial cells obtained from a 
1 mL sample, while mucosal DNA originated from 0.25 g 
mucin agar collected from the mucin beads. Homogenization 
was performed using a Fastprep-24 device (MP BioMedi-
cals, Illkirch, France) performed twice for 40 s at 4 m/s with 
a resting period of 5 min between shakings.
Subsequently, quantitative polymerase chain reaction 
(qPCR) for the Firmicutes phylum, the Bacteroidetes phy-
lum, Akkermansia muciniphila, Bifidobacterium spp. and 
Lactobacillus spp. was performed on a QuantStudio 5 Real-
Time PCR system (Applied Biosystems, Foster City, CA 
USA). Each sample was analysed in technical triplicate and 
outliers (more than 1  CT difference) were omitted. Different 
published qPCR methods were adopted for the Firmicutes 
and Bacteroidetes phyla [44], Akkermansia muciniphila 
[45], and Lactobacillus and Bifidobacterium spp [46, 47].
Statistics
Statistical analysis was performed in GraphPad Prism 8.3.0. 
Normality of data and equality of the variances were con-
firmed with a Shapiro–Wilk test and a Brown–Forsythe test, 
respectively. For metabolic analysis parameters, normally 
distributed data with equal variances were analysed using 
ANOVA with a Tukey post hoc test. For microbial com-
munity composition, data were analysed using multiple 
independent t tests with correction for multiple compari-
sons using the Holm–Sidak method. Multiplicity adjusted 
p values were implemented. Differences were considered 
significant if p < 0.05.
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Results
Analysis of the microbial metabolic activity
The SCFA profiles predominantly comprised acetate, 
propionate and butyrate. These are known to be the most 
abundant end points in colonic fermentation of dietary 
fibre [48] and provide conformation that the SHIME® 
simulation was working as expected. Changes in observed 
levels of these SCFAs across the control and treatment 
periods are shown in Fig. 6. ANOVA revealed signifi-
cant time effects following dosing with Cereboost® for 
all SCFAs in both colon regions. Main effects of time 
are reported in Table 2. Post hoc tests revealed that Cer-
eboost® significantly enhanced acetate levels compared 
to the control period in both colon regions (p = 0.043 and 
p = 0.001 at the end of the treatment period in the PC and 
DC, respectively). An average increase of 7.8 mmol/L 
(42.0%) and 6.2 mmol/L (21.2%) was observed in the PC 
and DC, respectively. In terms of propionate levels, it fol-
lowed that the treatment with Cereboost® resulted in sig-
nificantly increased propionate levels in the PC (p = 0.033 
at the end of the treatment period), i.e., an average increase 
of 1.77 mmol/L (37.9%) as compared to the control period. 
In the DC, the Cereboost® treatment also resulted in sig-
nificantly enhanced propionate levels (p = 0.001 at the 
end of the treatment period), with an average increase of 
1.96 mmol/L (24.1%). Butyrate levels were significantly 
enhanced upon treatment with the test product in both 
colon regions (p = 0.002 and p = 0.019 at the end of the 
treatment period in the PC and DC, respectively), with 
strongest effects observed in the PC (i.e., an average 
increase of 3.0 mmol/L (22.6%)). Overall, the increased 
acetate, propionate and butyrate levels in the PC and DC 
resulted in significantly enhanced total SCFA levels in 
Fig. 6  Increasing levels of acetate, propionate, butyrate, and total 
SCFA observed in a SHIME® simulation of the proximal and dis-
tal colon following a 3-week period of in  vitro treatment with Cer-
eboost®. *Indicates significant change in SCFA metabolic activ-
ity during weeks 1, 2, and 3 of treatment compared with the control 
period, error bars represent mean standard deviation
Table 2  ANOVA outcomes for SCFA analysis
SCFA Colon location Time effect  
F(3,8)
p value
Acetate Proximal 7.24 0.011
Acetate Distal 38.77  < 0.001
Propionate Proximal 11.34 0.003
Propionate Distal 40.39  < 0.001
Butyrate Proximal 22.82  < 0.001
Butyrate Distal 16.26 0.001
Total SCFA Proximal 19.00 0.001
Total SCFA Distal 50.19  < 0.001
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these colon regions (p = 0.005 and p = 0.001 at the end 
of the treatment period in the PC and DC, respectively).
Analysis of the microbial community composition
With respect to community composition, qPCR analysis 
was performed for targeted microbial groups (Table 3). 
Lactobacillus levels remained unaffected during treatment 
with Cereboost® in the luminal and mucosal PC. How-
ever, in the DC, Cereboost® supplementation resulted in 
enhanced Lactobacillus levels, with a clear trend in the 
mucosal environment (p = 0.066). Bifidobacterium levels 
decreased significantly in the mucosal environment of both 
the PC and DC during Cereboost® treatment (p = 0.004 
and p < 0.001, respectively). Overall, Bacteroidetes lev-
els remained largely unaffected during treatment with 
Cereboost®, with the exception a significant reduction in 
the mucosal DC (p = 0.001). Conversely, Firmicutes lev-
els were significantly reduced in all colonic areas upon 
Cereboost® supplementation. Finally, while Akkermansia 
muciniphila remained below the limit of detection in the 
mucosal environment, treatment with Cereboost® resulted 
in a significant enrichment of Akkermansia muciniphila 
levels in the luminal DC (p = 0.002).
Discussion
The emerging pattern of cognitive results highlighted a 
maintenance of executive function and working memory 
performance in the immediate postprandial period follow-
ing Cereboost® treatment, while chronic supplementation 
also offered some long-term benefits to performance accu-
racy and to subjective measures of mood and mental fatigue. 
In vitro Cereboost® treatment significantly increased SCFA 
(colonic acetate, propionate and butyrate levels), associated 
with increases in Akkermansia muciniphila and Lactobacil-
lus levels.
The acute maintenance of performance on the ANT task 
is consistent with previous acute findings [6, 7]. In particu-
lar, these executive function effects are likely to result from 
activation of the prefrontal cortex (PFC), as observed in pre-
vious research [49]. Initially, acute effects were observed for 
ANT accuracy and reaction time at only one or two of the 
test sessions, but the acute-on-chronic effects observed for 
the ANT task were evident across the full day of cognitive 
testing, lasting up to 6 h. Additional acute-on-chronic effects 
were observed for the switching and Corsi tasks (measures 
of executive function and working memory, respectively), 
that were not apparent during the preliminary acute test-
ing visit. This suggests that chronic supplementation may 
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supplementation also offered some sustained long-term ben-
efits. In particular, chronic supplementation was observed to 
decrease error rates on the RVIP task, though corresponding 
acute benefits were not observed for the same task. Simi-
larly, no acute benefits of Cereboost® have been observed 
for RVIP performance in previous research [6]; therefore, 
chronic treatment seems to be necessary to observe benefits 
in this specific cognitive domain. Chronic supplementation 
with Cereboost® also offered some long-term benefits for 
subjective measures of mood (self-assurance) and mental 
fatigue. Such mood effects are likely to indirectly impact 
cognitive performance; increased self-assurance may reflect 
greater confidence to perform a cognitive task well, and 
lower levels of mental fatigue may help to maintain focus 
during a cognitive task. Indeed, similar mood and fatigue 
changes have been associated with better cognitive perfor-
mance in previous research [50].
However, a notable observation from the current study 
was a lack of acute improvements to mood, and a lack of 
acute or chronic episodic memory benefits. Previously, fol-
lowing a 100 mg dose of P. quinquefolius, acute improve-
ments in a Bond-Lader “Calmness” factor were observed in 
young adults [6]. However, the effect was not replicated in 
middle-aged adults when using a higher dose [7]. Therefore, 
it appears possible that P. quinquefolius may not facilitate 
broad improvements to mood at the dose used in the current 
study. Here, no changes to positive affect, negative affect or 
mental fatigue were observed during the immediate post-
prandial period, although benefits to mental fatigue and self-
assurance were subsequently observed after daily treatment 
for 14 days. Episodic memory effects have previously been 
observed following a similar acute dose [6], however differ-
ences in methodology (such as number of words presented, 
mode of presentation, and mode of recall) may explain 
differences in observed effects. A more sensitive episodic 
memory task such as Reys Auditory Verbal Learning Task 
(RAVLT) may be better suited to the investigation of acute 
memory changes, rather than the simplified task used here. 
Daily supplementation over a two-week period also failed to 
elicit an episodic memory effect in the current study. Short-
term (working) memory effects were observed for the Corsi 
task during this time frame. However, benefits to long-term 
memory may require an extended supplementation period. 
It is also possible that the predominantly female sample 
tested may have influenced this memory outcome. Women 
are known to have an episodic memory advantage over men 
[51] and, although the memory recall scores obtained here 
don’t appear particularly high, memory improvements fol-
lowing Cereboost® treatment may, therefore, be more preva-
lent in males or in cognitively impaired populations such as 
older adults with age-related memory decline, rather than 
the cognitively intact young population tested here. The 
pre-clinical literature supports this theory, with a number of 
studies observing neuroprotective memory effects of ginseng 
in rodent models of ageing and neurodegenerative disease 
[4]. Therefore, it is recommended to investigate the memory 
effects of Cereboost® in an older adult population.
There are several possible underlying mechanisms of 
action that could explain the cognitive and mood changes 
that were observed in the current study following treat-
ment with Cereboost®. For example, acetylcholine plays an 
important role in the modulation of cognition and affect, 
and acetylcholine-related pathways of neurotransmission 
are already known to be impacted by P.quinquefolius [13]. 
The chronic mood and fatigue effects observed here may 
therefore be due to facilitation of acetylcholine neurotrans-
mission. Indeed, caffeine [52] and other natural extracts 
[53, 54] are known to promote benefits to mental fatigue, 
through inhibition of acetylcholine esterase [55]. With 
respect to cognition, RVIP was previously reported to be 
an acetylcholine-sensitive task following observed increases 
and decreases in task performance after treatment with an 
acetylcholine agonist (scopolamine) and an acetylcho-
line antagonist (nicotine), respectively [35]. In the current 
study, chronic treatment with Cereboost® seems to provide 
a beneficial effect on the RVIP task, thereby suggesting an 
acetylcholine-related mechanism of action for long-term 
cognitive improvements.
Acute benefits to RVIP performance were not observed 
in the current study. It is possible, however, that an acute 
200 mg dose of Cereboost is insufficient to impact acetyl-
choline. Indeed, other previous research similarly failed to 
observe any effects of acute Cereboost® on RVIP perfor-
mance [6]. One potential limitation of the current study 
design is that participants were required to abstain from 
caffeine for 24 h prior to test visits. The intention was to 
minimise the confounding effects of caffeine on cognitive 
function. However, habitual caffeine consumption was not 
determined and so participants may have been in caffeine 
withdrawal at the time of acute testing. This may have 
impacted any acute acetylcholine response, and so caffeine 
intake should be considered in any future research.
Emerging evidence also suggests that the gut microbiome 
may impact cognitive function and mood, in part due to the 
facilitation of effective digestion and metabolism of bioac-
tive compounds in food. The health of the gut microbiome 
is largely dependent on diet quality. Diets high in fruit and 
vegetables are most beneficial for a healthy gut microbiota 
profile. The reported habitual fruit and vegetable consump-
tion of the participants in the current study is in line with 
current UK recommended guidelines of 5 portions per day. 
However, these values were calculated via food frequency 
questionnaire and so may be overestimated [56]. Recent 
nutritional research also suggests that much higher fruit 
and vegetable intakes may be preferable for the optimisa-
tion of gut microbiota; a study investigating the benefits of 
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increased fruit and vegetable intake observed benefits to gut 
health following the addition of up to 6 extra portions per 
day, on top of previous habitual intake levels (though these 
initial levels were not reported) [57]. Therefore, irrespec-
tive of the habitual intake of the student participants here, 
it remains possible that their microbiome was not optimal 
at the start of the in vivo study, with potential to improve 
following Cereboost® treatment. Indeed, during the present 
in vitro study using a donor sample from a young adult of 
similar demographic to the cognitive participants, signifi-
cant increases in SCFA levels and Akkermansia muciniphila 
abundance, and a clear trend towards increased Lactobacil-
lus levels, were observed across three weeks of Cereboost® 
supplementation. These improvements to the gut micro-
biome model provide a potential mechanism of action for 
improvements to cognitive function by facilitating not only 
the absorption and metabolism of bioactive compounds pre-
sent in American ginseng, but potentially also the absorp-
tion of beneficial bioactive compounds found in habitually 
consumed foods.
It has been suggested that the gut microbiota play an 
important role in the bidirectional interactions between the 
central and the enteric nervous system, thereby likely affect-
ing cognitive function [58]. Effective treatment paradigms 
for improving the gut microbiota profile include high-fibre 
diets, prebiotics, and probiotics [59]. In the current in vitro 
study, Cereboost® has demonstrated a prebiotic effect result-
ing in increased metabolite production as well as modula-
tion of the microbial community composition. Therefore, 
it can be hypothesised that microbial modulation might be 
involved in the observed cognitive improvements following 
Cereboost® supplementation. Modulation of gut microbiota 
and resultant increases in SCFA production have been impli-
cated in gut–brain signaling pathways including immune 
(neuroinflammatory response, mood), endocrine (learning 
and memory), vagal/neural (learning and memory) and 
humoral pathways (stress, neuroprotection) [60]. Indeed, this 
mechanism is consistent with both the chronic benefits of 
Cereboost® observed here, and the increase in acute benefits 
observed after a period of chronic supplementation.
As an important caveat, the supplementation period 
used for the SHIME® study was a week longer than the 
cognitive intervention in the current study. The changes to 
the gut microbial community were determined by compar-
ing pre-treatment bacteria levels with post-treatment lev-
els, but as sampling only occurred once per week during 
the treatment period, an average was calculated across the 
three weeks of treatment. This made it impossible to deter-
mine whether microbiota levels had significantly changed 
after two weeks. However, significant SCFA changes (gen-
erally associated with increased microbial activity) were 
observed after only one or two weeks, as shown in Fig. 6. 
Given these increased SCFA levels observed during this 
shorter period, it appears likely then that alterations to 
the gut microbiota remain a viable mechanism by which 
cognitive changes could be effected after only two weeks 
of daily Cereboost® treatment. One further caveat is that 
these changes to gut microbiome were observed in vitro, 
rather than in the cognitive study participants, and so it 
will be critical for future research to provide an in vivo 
link between changes in gut microbiota and cognitive 
changes in the same host (either animal or human). A fur-
ther limitation in the current study is that participants were 
predominantly female, while the faecal donor was male, 
so future studies should seek to confirm the cognitive and 
gut microbiota effects of Cereboost® in a representative 
sample of both males and females. This would also allow 
determination of any sex differences in observed effects.
In conclusion, this study confirmed the promising 
effects of Cereboost® on cognitive function. Acute ben-
efits to working memory and executive function were 
further improved following a two-week period of daily 
supplementation. Daily supplementation with Cereboost® 
also benefitted performance accuracy, mood and mental 
fatigue. Results from the concurrent in vitro study suggest 
a possible mechanism of action, via changes to the gut 
microbiome, potentially underlying the observed improve-
ments to cognitive function. Chronic improvements to 
RVIP task performance also suggest that acetylcholine 
pathways of neurotransmission may be implicated. Further 
studies will be required to fully unravel the mechanisms 
involved.
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